


CHMC7.001CPI



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : J. Whitsett
Appl. No. : 09/558,576
Filed : April 26, 2000
For : SURFACTANT PROTEIN D
FOR THE PREVENTION AND
DIAGNOSIS OF PULMONARY
EMPHYSEMA
Examiner : P. Robinson

Group Art Unit 1853

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

2 MAY 2001
(Date)

James J. Mullen III, Ph.D., Reg. No. 44,957

SECOND REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

A Request for Corrected Filing Receipt was filed on January 3, 2001, requesting that the Official Filing Receipt is corrected to reflect the true name of the applicant, **Jeffrey A. Whitsett, M.D.** that was correctly stated on the Declaration filed September 19, 2000. A Corrected Filing Receipt was mailed March 26, 2001, a copy of which is enclosed, which still reflects the incorrect name of the inventor as James A. Whitsett, M.D. Applicant hereby requests for a second Corrected Filing Receipt to be mailed reflecting the true name of the applicant.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2 MAY 2001

By: James J. Mullen III, Ph.D.

Registration No. 44,957
Customer No. 20,995



DEA/JAH

UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS AND CLAIMS
09/558,576	04/26/2000	1632	1523	CHMC7.001CP1	15	28

CONFIRMATION NO. 9558

CORRECTED FILING RECEIPT



OC00000005902160

20995

 KNOBBE MARTENS OLSON & BEAR LLP
 620 NEWPORT CENTER DRIVE
 SIXTEENTH FLOOR
 NEWPORT BEACH, CA 92660

Date Mailed: 03/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) **Jeffrey**~~James A. Whitsett M.D., Cincinnati, OH;~~

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/104,941 10/20/1998

Foreign Applications

If Required, Foreign Filing License Granted 07/10/2000

Projected Publication Date:

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Surfactant protein D for the prevention and diagnosis of pulmonary emphysema

Preliminary Class


800

Data entry by : SHEFFEY, CATHERINE

Team : 1600

Date: 03/26/2001





**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

